Indeed, objective responses in PD-L1-negative patients—usually between 11–20%—have been reported in the literature, whilst melanoma patients reached an overall response of 41% with nivolumab monotherapy, and 54% with nivolumab plus ipilimumab in the CheckMate 067 study [197]. This evidence concerns the gene CD274 and melanoma.